ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 7, 2025
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase
Read more at globenewswire.com20.33
-0.13 (-0.64%)
Find more stocks in the Stock Screener
ADMA Latest News and Analysis
2 days ago - ChartmillADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth StockADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech sector.
